Vertex Pharmaceuticals (VRTX)
Coverage summary
Aardvark Labs Capital Research has covered Vertex Pharmaceuticals (VRTX) since May 5, 2026. The company is in the Healthcare sector. This page lists 3 reports: 3 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published November 5, 2026. The current rating is Hold, the same in every report since coverage began.
Translations: 2 in Chinese.
All VRTX reports
2026-11-05
Recap: Q3 2026
Vertex's Guidance Raise Is Bought, Not Grown, and the Fourth Quarter Carries the Crinetics Bill
2026-08-04
Recap: Q2 2026
Vertex Raises Revenue, Not Earnings, and Buys a Fifth Pillar That Does Not Pay Until 2029
2026-05-05
Recap: Q1 2026
The Switch Works, the Launches Slip: Initiating Vertex at Hold on a Guide That Turns 8% Revenue Growth Into 3% EPS Growth